Antibody-dendrimer conjugates: the number, not the size of the dendrimers, determines the immunoreactivity.
Radioimmunotherapy using antibodies with favorable tumor targeting properties and high binding affinity is increasingly applied in cancer therapy. The potential of this valuable cancer treatment modality could be further improved by increasing the specific activity of the labeled proteins. This can be done either by coupling a large number of chelators which leads to a decreased immunoreactivity or by conjugating a small number of multimeric chelators. In order to systematically investigate the influence of conjugations on immunoreactivity with respect to size and number of the conjugates, the anti-EGFR antibody hMAb425 was reacted with PAMAM dendrimers of different size containing up to 128 chelating agents per conjugation site. An improved dendrimer synthesis protocol was established to obtain compounds of high homogeneity suitable for the formation of defined protein conjugates. The quantitative derivatization of the PAMAM dendrimers with DOTA moieties and the characterization of the products by isotopic dilution titration using (111)In/(nat)In are shown. The DOTA-containing dendrimers were conjugated with high efficiency to hMAb425 by applying Sulfo-SMCC as cross-linking agent and a 10- to 25-fold excess of the thiol-containing dendrimers. The determination of the immunoreactivities of the antibody-dendrimer conjugates by FACS analysis revealed a median retained immunoreactivity of 62.3% for 1.7 derivatization sites per antibody molecule, 55.4% for 2.8, 27.9% for 5.3, and 17.1% for 10.0 derivatization sites per antibody but no significant differences in immunoreactivity for different dendrimer sizes. These results show that the dendrimer size does not influence the immunoreactivity of the derivatized antibody significantly over a wide molecular weight range, whereas the number of derivatization sites has a crucial effect.
Wängler
C
C
Universitaetsklinikum Heidelberg, Abteilung Nuklearmedizin, Germany.
Moldenhauer
G
G
Eisenhut
M
M
Haberkorn
U
U
Mier
W
W
D000906:Antibodies / Q000737:chemistry / Q000276:immunology* / Q000378:metabolism*; D000911:Antibodies, Monoclonal / Q000276:immunology; D045744:Cell Line, Tumor; D050091:Dendrimers / Q000737:chemistry / Q000378:metabolism*; D066246:ErbB Receptors / Q000276:immunology; D006573:Heterocyclic Compounds, 1-Ring / Q000276:immunology / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry* / Q000276:immunology*; D011073:Polyamines / Q000276:immunology / Q000378:metabolism
D000906:Antibodies; D000911:Antibodies, Monoclonal; D050091:Dendrimers; D006573:Heterocyclic Compounds, 1-Ring; D018796:Immunoconjugates; C104700:PAMAM Starburst; D011073:Polyamines; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; C512478:EGFR protein, human; D066246:ErbB Receptors